← Eichor
Study identifier: NCT06463665 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Condition: Advanced Non-squamous Non-small-cell Lung Cancer · Advanced Squamous Non-Small Cell Lung Carcinoma · Metastatic Non-squamous Non Small Cell Lung Cancer  ·  Sponsor: Genelux Corporation

PhasePhase 2
Planned participants142
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (15)

Pioneer Research Center, LLCBullhead City, Arizona, United StatesRecruiting
Clermont Oncology CenterClermont, Florida, United StatesRecruiting
Oncology & Hematology Associates of West BrowardCoral Springs, Florida, United StatesRecruiting
Helios Clinical ResearchFort Lauderdale, Florida, United StatesRecruiting
Bioresearch PartnerHialeah, Florida, United StatesRecruiting
University of Miami - Sylvester Comprehensive Cancer CenterMiami, Florida, United StatesRecruiting
Bioresearch PartnerMiami, Florida, United StatesRecruiting
Mid Florida Hematology and Oncology CenterOrange City, Florida, United StatesRecruiting
BRCR Medical Center, Inc.Plantation, Florida, United StatesRecruiting
Michigan Hematology and Oncology ConsultantsDearborn, Michigan, United StatesRecruiting
Oakland Medical GroupFarmington Hills, Michigan, United StatesRecruiting
Inspira Medical Center Mullica HillMullica Hill, New Jersey, United StatesRecruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06463665